Company Overview
Company Type: Private Company
Website: www.matitherapeutics.com/about/corporate-overview
Global Number of Employees (Latest): -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 2.01
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Mati Therapeutics Inc. offers delivery system to deliver drugs to the surface of the eye through the tear film. The company was incorporated in 2012 and is based in Austin, Texas.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
-
Net Debt
-
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Muller, Christopher Augustine
COO & Executive Director
Utkede, Deepank
Executive Director

Key Board Members
Name
Title
Muller, Christopher Augustine
COO & Executive Director
Utkede, Deepank
Executive Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
101 Colorado Avenue Suite 2409 | Austin, TX | 78701 | United States
Phone: 512-720-1333   


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
QLT Inc., Assets Related To Punctal Plug Drug Delivery System Technology
As of April 3, 2013, assets related to punctal plug drug delivery system technology of QLT Inc. were acquired by Mati Therapeutics Inc. Assets Related To Punctal Plug Drug Delivery System Technology of QLT Inc. comprises assets that develop drugs for the eyes. The platform technology builds ocular devices and punctal plugs used by ophthalmologists or optometrists.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-11-2019
May-24-2019
Private Placement
Target
Mati Therapeutics Inc.


0.17
Oct-01-2018
Oct-16-2018
Private Placement
Target
Mati Therapeutics Inc.


0.05
Sep-30-2014
Oct-10-2014
Private Placement
Target
Mati Therapeutics Inc.


0.15
Apr-4-2013
Apr-3-2013
Merger/Acquisition
Buyer
QLT Inc., Assets Related To Punctal Plug Drug Delivery System Technology
Mati Therapeutics Inc.
QLT Inc. (nka:Novelion Therapeutics Inc.)
20.25
Apr-3-2013
-
Private Placement
Target
Mati Therapeutics Inc.


1.13
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-26-2023
Executive/Board Changes - Other
Mati Therapeutics Inc. Announces Promotion of Chris Muller to Chief Operating Officer
Sep-12-2023
Business Expansions
Mati Therapeutics Inc. Announces Completion of Manufacturing Facility Dedicated to Global Production of All Punctal Plug Delivery System (Ppds) Products
Feb-08-2021
Product-Related Announcements
Mati Therapeutics Inc. Announces Positive Results for Sustained Delivery Platform in Post-Op Pain and Inflammation
May-24-2019
Private Placements
Mati Therapeutics Inc. announced that it has received $0.16503 million in funding
May-11-2019
Private Placements
Mati Therapeutics Inc. announced a financing transaction

M&A Advisors
Latham & Watkins LLP


Advisors
M&A Advisors
Latham & Watkins LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Apr-30-2019
Apr-26-2019
Ocular Therapeutix, Inc. (NasdaqGM:OCUL)
SEC
8-K (8.01, 9.01)
32 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Muller, Christopher Augustine
COO & Executive Director
512-720-1333
-

Utkede, Deepank
Executive Director
512-720-1333
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Muller, Christopher Augustine
COO & Executive Director
512-720-1333
-

Utkede, Deepank
Executive Director
512-720-1333
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
